Nov 9, 2010
Novartis AG plans to seek regulatory approval within 18 months for a pioneering tablet containing an embedded microchip, bringing the concept of “smart-pill” technology a step closer.
The initial program will use one of the Swiss firm’s established drugs taken by transplant patients to avoid organ rejection. But Trevor Mundel, global head of development, believes the concept can be applied to many other pills.
“We are taking forward this transplant drug with a chip and we hope within the next 18 months to have something that we will be able to submit to the regulators, at least in Europe,” Mundel told the Reuters Health Summit in New York.
“I see the promise as going much beyond that,” he added.
Novartis agreed in January to spend $24 million to secure access to chip-in-a-pill technology developed by privately owned Proteus Biomedical of Redwood City, California, putting it ahead of rivals.
This article was posted: Tuesday, November 9, 2010 at 4:35 am